急性冠脉综合征患者基因分型对血小板聚集率影响的研究

doi:10.3969/j.issn.1000-8535.2016.05.007

广州医药 ›› 2016, Vol. 47 ›› Issue (5): 20-22.DOI: 10.3969/j.issn.1000-8535.2016.05.007

急性冠脉综合征患者基因分型对血小板聚集率影响的研究

吕磊, 谭文亮, 吴天源, 孙少喜

广州市第一人民医院心内科(广州 510180)

收稿日期:2016-05-23 出版日期:2016-09-20 发布日期:2021-12-02
通讯作者: 吕磊,E-mail:13826255547@139.com
基金资助:
广东省科技厅计划项目(2012B031800341)

Study of CYP2C19 gene polymorphisms influencing on platelet aggregation rate

Lv Lei, Tan Wenliang, Wu Tianyuan, et al

Guangzhou First People's Hospital, Guangzhou 510180, China

Received:2016-05-23 Online:2016-09-20 Published:2021-12-02

摘要/Abstract

摘要： 目的探讨CYP2C19不同基因分型对急性冠状动脉综合征(ACS)患者服用氯吡格雷后血小板聚集率的影响。方法选取2015年1月—2016年3月入住心内科的ACS患者258例为研究对象。入院时及服用氯吡格雷三日后分别抽取静脉血检测血小板聚集率及CYP2C19基因型。结果快代谢型组(extensive metabolisers, EM)和中代谢型组(intermediate metabolisers, IM)服药前后血小板最大聚集率分别为(58.76±15.45)% vs(35.17±10.26)%和(59.35±11.58)% vs(47.66±12.59)%(P<0.05), 而慢代谢型组(poor metabolisers, PM)的血小板最大聚集率无明显降低。快代谢型组的最大血小板聚集率的降低幅度比慢代谢型组大(23.58±12.39% vs 11.65±13.56%,P<0.05)。共有33例(12.79%)患者为氯吡格雷抵抗, 其中快代谢型组中氯吡格雷抵抗者2例(1.67%), 中代谢型组中氯吡格雷抵抗者3例(2.80%), 慢代谢型组中氯吡格雷抵抗者28例(90.32%) (三组比较P=0.038)。结论 ACS患者CYP2C19基因分型与服用氯吡格雷后血小板最大聚集率有关,与氯吡格雷抵抗有关。

关键词: 血小板聚集率, 基因分型, CYP2C19, 急性冠脉综合征

Abstract: Objective To explore the relationship between platelet aggregation rate and CYP2C19 gene polymorphisms. Methods A total of 258 cases diagnosed as acute coronary syndrome (ACS) from January 2015 to March 2016. The platelet aggregation rate was tested before and 3 days after taking clopidogrel. CYP2C19 gene polymorphisms was tested by Gene chip hybridization technique. Results The platelet aggregation rate before and after taking clopidogrel was(58.76±15.45)% vs(35.17±10.26)% and(59.35±11.58)% vs(47.66±12.59)%(P<0.05)in EM group and IM group. But there was no change in PM group. The PM group were associated with a significant increase risk of clopidogrel resistance compared with EM group and IM group. Conclusion CYP2C19 gene polymorphisms influence the rate of platelet aggregation rate after taking clopidogrel and are associated with clopidogrel resistance in ACS patients.

Key words: Clopidogrel, Gene polymorphism, CYP2C19, Acute coronary syndrome

吕磊, 谭文亮, 吴天源, 孙少喜. 急性冠脉综合征患者基因分型对血小板聚集率影响的研究[J]. 广州医药, 2016, 47(5): 20-22.

Lv Lei, Tan Wenliang, Wu Tianyuan, et al. Study of CYP2C19 gene polymorphisms influencing on platelet aggregation rate[J]. Guangzhou Medical Journal, 2016, 47(5): 20-22.

参考文献

[1] SZAPARY L,KOLTAI K,TIBOLD A,et al. Clopidogrel resistance in cerebrovascular disease-results of one-year follow-up[J]. Orv Hetil,2015,156(10):53-59.
[2] WAND S,BARO D,BAECKER C,et al. Response to dual antiplatelet therapy in patients with peripheral artery occlusive diseasesuffering from critical limb ischemia[J]. Clin Lab,2014,60(8):1601-1607.
[3] 陈希伟,吴同果,韦建瑞,等. 复方丹参滴丸对氯吡格雷抵抗患者血小板聚集功能影响的研究[J]. 广州医药, 2012, 43(2): 26-29.
[4] GAO W,ZHANG Q,GE H,et al. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation[J]. Angiology,2013,64(9):554-558.
[5] AL-AZZAM SI, ALZOUBI KH, KHABOUR OF, et al. Factors that contribute to clopidogrel resistance in cardiovascular disease patients:environmental and genetic approach[J]. Int J Clin Pharmacol Ther,2013,51(6):179-186.
[6] SAMOS M, SIMONOVA R, KOVIR F, et al. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis[J]. Am J Emerg Med, 2014, 32 (3): 461-465.
[7] PRIYADHARSINI R,SHEWADE DG,SUBRAJA K,et al. Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population[J]. Mol Biol Rep,2014,41(10):7265-7271.
[8] ANDERSON JL, ADAMS CD, ANTMAN EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the AmericanCollege of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine[J]. Circulation, 2012, 126(7):875-876.
[9] ANTMAN EM, HAND M, ARMSTRONG PW, et al. 2007 Focused Update of the ACC /AHA 2004 Guidelines for the Management of Patients With ST.Elevation Myocardial Infarction:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians:2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Writing on Behalf of the 2004 Writing Committee[J]. Circulation, 2008,1 17(5):296-329.
[10] 李建华,曹剑,范利. 氯吡格雷抵抗临床防治的研究进展[J]. 中华老年心脑血管病杂志,2015, 17(12):1324-1326.
[11] FRELINGER AL, BHATT DL, LEE RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1,PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function[J]. J Am Coll Cardiol, 2013, 61(8): 872-879.
[12] SCOTT SA,SANGKUHL K,GARDNER EE,et al. Clinical pharmacogenetic simplementation consortium guidelines for cytochrome P450-2C19( CYP2C19) genotype and clopidogrel therapy[J]. Clinical Pharmacology and Therapeutics, 2011, 90(5): 328-331.
[13] TRENK D, STONE GW, GAWAZ M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high plateletreactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study [J]. J Am Coll Cardiol, 2012, 59(24): 2159-2164.
[14] SIMON T, VERSTUYFT C, MARY-KRAUSE M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl JMed, 2009, 360(4): 363-375.
[15] STONE GW, WITZENBICHLER B, WEISZ G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drugeluting stents (ADAPT-DES): a prospective multicentre registry study[J]. Lancet, 2013, 382(9): 614-623.
[16] 赵榆华,傅宴,雷婷,等. 替格瑞洛联合比伐卢定对STEMI急诊PCI无复流临床研究[J]. 现代医院, 2014, 14(8):30-32.

急性冠脉综合征患者基因分型对血小板聚集率影响的研究

Study of CYP2C19 gene polymorphisms influencing on platelet aggregation rate

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价